RESUMO
Dermatitis cruris pustulosa et atrophicans (DCPA) is a benign inflammatory skin disease of the younger population in the tropics. Although this pustular skin condition of particular topography is frequently seen by dermatologists in tropical countries, its origin remains unknown. We report the case of a young woman with DCPA associated with prurigo nodularis. A bacterial origin has not been demonstrated in this case. Histology showed an intraepidermal neutrophilic pustule with dermal and subcutaneous infiltration by neutrophils and eosinophils forming flame figures. Different pathogenic hypotheses are discussed with special regard to a potential relationship between DCPA and eosinophilic cellulitis.
Assuntos
Dermatoses da Perna/patologia , Dermatopatias Vesiculobolhosas/patologia , Pele/patologia , Adolescente , Burkina Faso , Eosinófilos , Feminino , Humanos , Dermatoses da Perna/complicações , Neutrófilos , Prurigo/complicações , Prurigo/patologia , Dermatopatias Vesiculobolhosas/complicaçõesAssuntos
Dermatopatias Parasitárias/diagnóstico , Viagem , Trypanosoma brucei gambiense/isolamento & purificação , Tripanossomíase Africana/diagnóstico , Adulto , Idoso , Animais , Anticorpos Antiprotozoários/sangue , Eritema/parasitologia , França , Gabão , Humanos , Imunoglobulina G/sangue , Imunoglobulina M/sangue , Masculino , Pentamidina/administração & dosagem , Resultado do Tratamento , Tripanossomicidas/administração & dosagem , Tripanossomíase Africana/complicações , Tripanossomíase Africana/parasitologiaRESUMO
The efficacy of fluconazole was evaluated in 35 travelers with parasitologically proven imported Old World cutaneous leishmaniasis (CL). Leishmania major (mainly MON-25) was identified in 15 patients and strongly suspected given the transmission area in 12 of these patients. Daily oral fluconazole (200 mg/day for adults and 2.5 mg/kg/day for children) was prescribed for six weeks. Outcome definition was based on re-epithelialization rate at day 50. Of the 27 L. major-infected patients, 12 (44.4%) were cured. This cure rate is similar to the placebo cure rate from trials in L. major CL in which, as in the present report, the definition of outcome relied exclusively on re-epithelialization. These data question the assumption that oral fluconazole is consistently effective for treatment of CL caused by L. major.
Assuntos
Antiparasitários/uso terapêutico , Evolução Biológica , Fluconazol/uso terapêutico , Leishmaniose Cutânea/tratamento farmacológico , Viagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Antiparasitários/efeitos adversos , Criança , Pré-Escolar , Feminino , Fluconazol/efeitos adversos , Humanos , Lactente , Leishmania/efeitos dos fármacos , Masculino , Pessoa de Meia-IdadeRESUMO
A patient with an ulcerated cutaneous leishmaniasis of the pinna had suppurative otochondritis after a first unsuccessful course of treatment with meglumine antimoniate. Although the Leishmania ulceration healed after a second course of meglumine antimoniate, and despite three oral dicloxacillin or pristinamycin courses, the otochondritis extended and an abscess developed. Pus from the abscess revealed a pure culture of Pseudomonas aeruginosa. Five days of oral ciprofloxacin plus rifampin led to a marked improvement. The P. aeruginosa isolate was sensitive to ciprofloxacin but fully resistant to rifampin. Healing with minimal mutilation was obtained at the end of a six-week course of multiple antibiotic therapy. Pseudomonas aeruginosa otochondritis was a co-factor of cartilage mutilation in this patient. Thus, infection with P. aeruginosa should be promptly treated when present in tender cutaneous or mucosal leishmaniasis lesions near cartilaginous areas.
